{
    "clinical_study": {
        "@rank": "68969", 
        "acronym": "CIN", 
        "arm_group": [
            {
                "arm_group_label": "placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "taking atorvastatin like placebo 12 hours before the procedure"
            }, 
            {
                "arm_group_label": "long term statin group", 
                "arm_group_type": "No Intervention", 
                "description": "taking atorvastatin for a long time before entering the study (their routine treatment)"
            }, 
            {
                "arm_group_label": "preoperation statin group", 
                "arm_group_type": "Experimental", 
                "description": "taking atorvastatin 12 hours before the procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "As the effect of statin use before the angiography to prevent contrast induced nephropathy\n      (CIN) is not well-known, the aim of the current study is to assess the effect of\n      atorvastatin on prevention of CIN in patients undergoing coronary angiography."
        }, 
        "brief_title": "Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography", 
        "condition": "Contrast Induced Nephropathy", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  having chronic stable angina who were referred for coronary angiography\n\n          -  non-pregnant female subjects\n\n          -  no history of diabetes mellitus\n\n          -  no history of renal failure\n\n          -  no history of single kidney\n\n          -  no history of cardiogenic shock\n\n          -  no history of unstable angina\n\n          -  no history of myocardial infarction\n\n          -  no history of hypersensitivity to statins\n\n          -  no history of previous intravascular contrast injection during one month before\n             admission\n\n        Exclusion Criteria:\n\n          -  glomerular filtration rate (GFR) <60\n\n          -  cardiogenic shock"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "April 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113540", 
            "org_study_id": "Grant number: 392172"
        }, 
        "intervention": {
            "arm_group_label": "preoperation statin group", 
            "intervention_name": "Atorvastatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "coronary angiography", 
            "chronic stable angina", 
            "CIN"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "pbidram2000@yahoo.com", 
                "last_name": "payman bidram, resident, MD", 
                "phone": "0989131102802"
            }, 
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CIN is determined as an increase in post-procedural serum creatinine of > 0.5 mg/dl or > 25% from baseline in the absence of any other causes", 
            "measure": "Contrast induced nephropathy (CIN) incidence", 
            "time_frame": "48 hours after the procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113540"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "peyman bidram", 
            "investigator_title": "Dr peyman bidram", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "serum creatinine (Cr) level", 
            "time_frame": "48 hours after the procedure"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}